Logo image of AFME.PA

AFFLUENT MEDICAL SA (AFME.PA) Stock Fundamental Analysis

Europe - EPA:AFME - FR0013333077 - Common Stock

1.455 EUR
-0.02 (-1.69%)
Last: 10/6/2025, 7:00:00 PM
Fundamental Rating

1

Taking everything into account, AFME scores 1 out of 10 in our fundamental rating. AFME was compared to 60 industry peers in the Health Care Equipment & Supplies industry. AFME may be in some trouble as it scores bad on both profitability and health. AFME is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AFME has reported negative net income.
AFME had a negative operating cash flow in the past year.
In the past 5 years AFME always reported negative net income.
AFME had a negative operating cash flow in each of the past 5 years.
AFME.PA Yearly Net Income VS EBIT VS OCF VS FCFAFME.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

AFME has a worse Return On Assets (-24.22%) than 76.67% of its industry peers.
AFME has a Return On Equity of -48.69%. This is in the lower half of the industry: AFME underperforms 75.00% of its industry peers.
Industry RankSector Rank
ROA -24.22%
ROE -48.69%
ROIC N/A
ROA(3y)-25.74%
ROA(5y)-24.09%
ROE(3y)-47.78%
ROE(5y)-43.59%
ROIC(3y)N/A
ROIC(5y)N/A
AFME.PA Yearly ROA, ROE, ROICAFME.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

AFME has a worse Gross Margin (20.79%) than 85.00% of its industry peers.
AFME does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AFME.PA Yearly Profit, Operating, Gross MarginsAFME.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

3

2. Health

2.1 Basic Checks

AFME does not have a ROIC to compare to the WACC, probably because it is not profitable.
AFME has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AFME has been increased compared to 5 years ago.
AFME has a better debt/assets ratio than last year.
AFME.PA Yearly Shares OutstandingAFME.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 2024 10M 20M 30M
AFME.PA Yearly Total Debt VS Total AssetsAFME.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

AFME has an Altman-Z score of -0.82. This is a bad value and indicates that AFME is not financially healthy and even has some risk of bankruptcy.
AFME's Altman-Z score of -0.82 is on the low side compared to the rest of the industry. AFME is outperformed by 78.33% of its industry peers.
A Debt/Equity ratio of 0.48 indicates that AFME is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.48, AFME is in line with its industry, outperforming 48.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACC7.16%
AFME.PA Yearly LT Debt VS Equity VS FCFAFME.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.28 indicates that AFME should not have too much problems paying its short term obligations.
The Current ratio of AFME (1.28) is comparable to the rest of the industry.
AFME has a Quick Ratio of 1.28. This is a normal value and indicates that AFME is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AFME (1.28) is better than 63.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.28
AFME.PA Yearly Current Assets VS Current LiabilitesAFME.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

AFME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.69%, which is quite impressive.
EPS 1Y (TTM)23.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AFME will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.09% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-53%
EPS Next 2Y-26.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AFME.PA Yearly Revenue VS EstimatesAFME.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2024 2026 2027 5M 10M 15M
AFME.PA Yearly EPS VS EstimatesAFME.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AFME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AFME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFME.PA Price Earnings VS Forward Price EarningsAFME.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFME.PA Per share dataAFME.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as AFME's earnings are expected to decrease with -26.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.09%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AFME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AFFLUENT MEDICAL SA

EPA:AFME (10/6/2025, 7:00:00 PM)

1.455

-0.02 (-1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-30 2025-09-30
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners10.03%
Ins Owner ChangeN/A
Market Cap57.25M
Analysts86
Price Target3.72 (155.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)22.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.9
P/FCF N/A
P/OCF N/A
P/B 1.89
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.1
BVpS0.77
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.22%
ROE -48.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.79%
FCFM N/A
ROA(3y)-25.74%
ROA(5y)-24.09%
ROE(3y)-47.78%
ROE(5y)-43.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.1%
Cap/Sales 3.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.28
Altman-Z -0.82
F-Score6
WACC7.16%
ROIC/WACCN/A
Cap/Depr(3y)6.62%
Cap/Depr(5y)10.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.5%
EPS Next Y-53%
EPS Next 2Y-26.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.06%
OCF growth 3YN/A
OCF growth 5YN/A